At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 125 enrolled
Drug / intervention
MP-214 +1 moredrug
Likely dose
MP-214 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
In Brief
A Phase 3 clinical trial evaluating MP-214 and Risperidone for Schizophrenia. Completed, enrolled 125 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedJun 2012
Primary CompletionMar 2015
TodayJul 2026
First PostedJun 22, 2012
Enrollment StartMay 1, 2012
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.0 years ago
Interventions
MP-214drug
Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
Risperidonedrug
Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone